ROR1 and prostate carcinoma: We opted to treat PC3 since these cells represent an aggressive and clinically difficult to treat ARneg-AI cancer that demonstrated the highest levels of ROR1 expression in comparison to normal prostatic epithelial cells and other prostate cancer cell lines such as DU145.